Medexus Pharmaceuticals Inc. (TSE:MDP - Free Report) - Investment analysts at Raymond James lowered their FY2027 EPS estimates for Medexus Pharmaceuticals in a research note issued on Monday, February 3rd. Raymond James analyst M. Freeman now forecasts that the company will post earnings per share of $0.74 for the year, down from their prior forecast of $0.88. Raymond James has a "Strong-Buy" rating and a $4.00 price target on the stock. The consensus estimate for Medexus Pharmaceuticals' current full-year earnings is $0.16 per share.
MDP has been the subject of several other reports. Alliance Global Partners raised shares of Medexus Pharmaceuticals to a "strong-buy" rating in a research note on Monday, December 23rd. Stifel Nicolaus downgraded shares of Medexus Pharmaceuticals from a "buy" rating to a "hold" rating and lowered their price objective for the stock from C$6.00 to C$3.45 in a report on Friday. Ventum Cap Mkts upgraded shares of Medexus Pharmaceuticals to a "strong-buy" rating in a report on Friday, January 17th. Leede Financial upgraded Medexus Pharmaceuticals from a "moderate buy" rating to a "strong-buy" rating in a report on Wednesday, January 22nd. Finally, Stifel Canada cut Medexus Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Thursday. Two analysts have rated the stock with a hold rating, one has given a buy rating and four have issued a strong buy rating to the company's stock. According to MarketBeat, Medexus Pharmaceuticals has a consensus rating of "Buy" and a consensus price target of C$5.49.
View Our Latest Stock Analysis on MDP
Medexus Pharmaceuticals Stock Performance
Shares of Medexus Pharmaceuticals stock traded up C$0.16 on Wednesday, reaching C$3.21. 209,889 shares of the company's stock were exchanged, compared to its average volume of 199,440. The company has a market capitalization of C$78.74 million, a P/E ratio of 64.20 and a beta of 1.96. Medexus Pharmaceuticals has a 52 week low of C$1.47 and a 52 week high of C$5.56. The firm's 50-day moving average is C$3.54 and its two-hundred day moving average is C$2.83.
About Medexus Pharmaceuticals
(
Get Free Report)
Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
See Also
Before you consider Medexus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medexus Pharmaceuticals wasn't on the list.
While Medexus Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
